Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases

• Status: Terminated
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The patients carrying a complicated primary lung cancer brain metastases die in less than 3 months of delay disease in the absence of treatment. The median survival of these patients is approximately six months when the treatment associated with radiotherapy chemotherapy based on cisplatin is now the standard treatment. In most studies the patients die of their brain disease in one case only two, so it is likely that some patients do not require brain irradiation (prognosis in this case is linked to extra-cerebral disease ). The benefits for patients in group B (without systematic irradiation) are not to suffer the side effects of this radiation. The risks are in the same group to see brain metastases become symptomatic.

The role of cerebral radiotherapy in the patients treated with chemotherapy is unclear:

should all patients be irradiated systematically (since the "reference" treatment is involved and with the aim of obtaining better control of the brain lesions and maintaining a better neurological status) or should only the patients showing cerebral progression be irradiated (avoidance of possibly useless brain radiotherapy and its side effects). The aim of this study is to better determine the position of cerebral radiotherapy in this context.

Main objective:

determine whether there is a difference in terms of progression-free survival between a therapeutic strategy with initial systematic brain radiotherapy followed by chemotherapy cis-platine/alimta + / - Bevacizumab and strategy with an initial chemotherapy cis-platine/alimta + / - Bevacizumab associated with brain radiotherapy only in cases of cerebral progression in patients with NSCLC with asymptomatic brain metastases

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Intercommunal Creteil
• Collaborator: Groupe Francais De Pneumo-Cancerologie
• Treatments: Bevacizumab; Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

1. Patients with histologically or cytologically proven non-epidermoid, non-small cell lung cancer, non-EGFR (Epidermal Growth Factor Receptor)-mutated (or mutation test impracticable).

2. Patients with brain metastasis/metastases without neurosurgical indication.

3. Asymptomatic patients (without treatment or with stable steroids or antiepileptic treatments for ≥ 5 days prior to obtaining the baseline MRI of the brain, and ≥ 5 days prior to first dose of study treatment (Cycle 1, Day 1).

4. At least one lesion measurable according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria.

5. ECOG (Eastern Cooperative Oncology Group) Performance Status 0 - 1

6. No previous chemotherapy for this cancer, apart from adjunctive chemotherapy more than 18 months ago.

7. Prior surgery is authorized in case of documented recurrence or progression.

8. Adequate biological functions (hematologic, platelets, hemoglobin, hepatic function, alkaline phosphatases, ASAT (Aspartate transaminase) and ALAT (Alanine Aminotransferase); creatinine clearance).

9. For women: Effective contraception for women of childbearing age during treatment and for 6 months following treatment.

For men: They must be surgically sterile or accept the use of effective contraception until 6 months after the treatment period.

10. Patients of more than 18 years of age.

11. Estimated survival of at least 12 weeks.

12. Consent signed by the patient

Exclusion Criteria:

1. Patients presenting with a brain lesion eligible for curative treatment (neurosurgical).

2. Symptomatic brain metastasis/metastases in spite of symptomatic treatment.

3. Epidermoid carcinoma.

4. Con indication of Bevacizumab is furthermore

5. Patients presenting with a brain lesion eligible for curative treatment (neurosurgery or radiosurgery).

6. Symptomatic brain metastasis/metastases in spite of symptomatic treatment.

7. Epidermoid carcinoma.

8. Cons indication of Bevacizumab

9. Inability to take the folic acid or vitamin B12 vitamin supplementation or the dexamethasone premedication (or any equivalent corticosteroid), or any inability to comply with the study procedures.

10. History of cancer, with the exception of cervical cancer in situ, skin cancer other than melanoma, adequately treated low-grade prostatic cancer (Gleason score <6), unless this cancer was diagnosed and treated more than 5 years ago without any signs of recurrence.

11. Patients presenting with a systemic disorder which, in the investigator's opinion, compromises their participation in the study for reasons related to treatment safety or compliance.

12. Patients incapable of discontinuing their aspirin treatment when the dose is > 1300 mg/day or their non-steroidal anti-inflammatory treatment two days before the day, on the day and two days the day of administration of pemetrexed (Alimta).

13. Patients presenting with a 3rd sector (pleural effusion, ascites) which is clinically detectable and uncontrollable by simple measures of the evacuatory puncture type or other treatment before inclusion in the study.

14. Patients presenting with neuropathy of grade > 2 according to the criteria of CTC (Common toxicity Criteria) v3.0.

15. Patients whose foreseeable compliance or geographical distance renders monitoring difficult.

16. Pregnant or breast-feeding women.

17. Significant weight loss (≥ 10%) during the 6 weeks preceding inclusion in the study.

18. Vaccination against yellow fever within 30 days preceding inclusion in the study.

19. Cons-indication to taking steroids

20. Persons deprived of their liberty as a result of a judicial or administrative decision

21. Concomitant participation in another trial